The invention relates to compounds of formula (I) as follows: (I) wherein X.sup.1 and X.sup.2, identical or different, are NR.sup.5 or a sulfur atom, Y is a group (C.sub.1-C.sub.10)alkanediyl, Ar.sup.1 and Ar.sup.2, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C.sub.1-C.sub.6) alkyl, OR.sup.1, NR.sup.1R.sup.2 and COOR.sup.3 with R.sup.1 and R.sup.2, independently of each other, are a hydrogen atom, a (C-.sub.1-C.sub.6) alkyl group or a COR.sup.3 group, R.sup.3 and R.sup.4 independently of each other, are a hydrogen atom or a (C.sub.1-C.sub.6) alkyl group, and R.sup.5 is a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment. ##STR00001##

The invention relates to compounds of formula (I) as follows: (I) wherein X.sup.1 and X.sup.2, identical or different, are NR.sup.5 or a sulfur atom, Y is a group (C.sub.1-C.sub.10)alkanediyl, Ar.sup.1 and Ar.sup.2, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C.sub.1-C.sub.6) alkyl, OR.sup.1, NR.sup.1R.sup.2 and COOR.sup.3 with R.sup.1 and R.sup.2, independently of each other, are a hydrogen atom, a (C-.sub.1-C.sub.6) alkyl group or a COR.sup.3 group, R.sup.3 and R.sup.4 independently of each other, are a hydrogen atom or a (C.sub.1-C.sub.6) alkyl group, and R.sup.5 is a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment. ##STR00001##

The present invention provides NOS inhibitors such as iNOS inhibitors including alkylamine or heteroalkylamine derivatives, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and/or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.

The present invention provides NOS inhibitors such as iNOS inhibitors including alkylamine or heteroalkylamine derivatives, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and/or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.